Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

RegeneRx Biopharmaceuticals, Inc.

http://www.regenerx.com

Latest From RegeneRx Biopharmaceuticals, Inc.

New Drugs For Gastric Cancer, Liver Disease Among 14 Products Heading For EU Approval

Two orphan drugs are among a host of products that the European Medicines Agency’s human medicines committee has OKd for pan-EU approval.

Europe Drug Review

Second European Stelara Biosimilar Pits Sandoz Against Stada

Just days after the first European ustekinumab biosimilar launch, Sandoz has entered the fray with the second rival to Stelara, introducing its Samsung Bioepis-partnered Pyzchiva version to compete with Stada and Alvotech’s Uzpruvo.

Biosimilars Launches

Samsung Snags Second Soliris Biosimilar In US

Samsung Bioepis has received US FDA approval for its Epysqli eculizumab biosimilar to Soliris, only the second version to be authorized in the US. However, the company declined to comment on launch plans as litigation with originator Alexion remains ongoing.

Biosimilars Approvals

Cardurion Raises $260m To Advance First-In-Class Cardiovascular Drugs

The company’s series B venture capital will fund Phase IIb trials of PDE9 inhibitor CRD-750 in heart failure and a Phase IIa study of CaMKII inhibitor CRD-4730 in a rare arrhythmic disease.

Financing Cardiovascular
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Medical Devices
    • Biomaterials
  • Biotechnology
    • Large Molecule
UsernamePublicRestriction

Register